Roughly two out of every three people worldwide carry HSV-1. The World Health Organization estimates that 3.8 billion people under age 50, about 64% of the global population in that age range, are infected. In the United States, the number is lower and has been dropping: as of the most recent national survey data (2015–2016), about 48% of Americans aged 14 to 49 tested positive for HSV-1 antibodies.
Global vs. U.S. Prevalence
The 64% global figure from the WHO reflects how common childhood oral transmission remains in most parts of the world. In many regions of Africa, Southeast Asia, and Latin America, the majority of children acquire HSV-1 before adolescence, usually through casual contact like a kiss from a family member. By adulthood, infection rates in these areas often exceed 70%.
The United States sits well below the global average. CDC data from the National Health and Nutrition Examination Survey (NHANES) put U.S. prevalence at 48.1% among people aged 14 to 49 during 2015–2016. Women tested positive at slightly higher rates than men: 50.9% compared to 45.2%. These numbers only capture a specific age window, so the true percentage of all Americans carrying HSV-1, including older adults who have higher infection rates, is likely well above 50%.
Prevalence Has Been Declining in the U.S.
HSV-1 rates in the U.S. dropped by more than 11 percentage points between 1999 and 2016. In 1999–2000, about 59.4% of Americans aged 14 to 49 had HSV-1 antibodies. By 2015–2016, that figure had fallen to 48.1%. The decline appeared across all racial and ethnic groups tracked by the CDC: prevalence among non-Hispanic white Americans fell from 52.4% to 36.9%, among non-Hispanic Black Americans from 68.4% to 58.8%, and among Mexican-American individuals from 82.0% to 71.7%.
This decline is generally attributed to improved hygiene, smaller household sizes, and less physical contact during early childhood. Paradoxically, fewer childhood infections may be shifting some first exposures to adolescence and adulthood, when HSV-1 is more likely to be acquired through sexual contact and cause genital rather than oral infections.
Why Most People Don’t Know They Have It
The vast majority of people with HSV-1 never get a noticeable cold sore. Many are infected as young children and never develop symptoms, or their initial outbreak is so mild it gets mistaken for a chapped lip or canker sore. This is why population-level prevalence can only be measured through blood tests that detect antibodies, not through counting reported cases.
Even without symptoms, the virus remains in the body permanently and can reactivate. Studies using sensitive DNA detection methods found that people with oral HSV-1 shed the virus on roughly one-third of the days tested, regardless of whether they had visible sores. Less sensitive lab methods detected shedding on about 6% of days. The shedding rate varied enormously between individuals, from zero to over 90% of days monitored. This invisible shedding is the main reason HSV-1 spreads so efficiently through populations.
Age Makes a Big Difference
HSV-1 is a cumulative, lifelong infection, so prevalence climbs steadily with age. The 48% figure from the CDC covers ages 14 to 49, but among older adults the rate is considerably higher. By the time people reach their 60s and 70s, the majority carry HSV-1 antibodies. Younger Americans, particularly teenagers and young adults, now have some of the lowest infection rates ever recorded in the country, a direct result of the declining trend that started in the late 20th century.
This age pattern matters for understanding your own risk. If you’re a younger adult in the U.S. who has never had a cold sore, there’s a reasonable chance you haven’t been exposed. That’s less true if you’re over 50 or grew up in a region with higher transmission rates.
How Reliable Are HSV-1 Blood Tests?
The most widely used commercial blood test for HSV-1 antibodies has high sensitivity, around 99%, meaning it catches nearly all true infections. Its specificity is lower, about 77%, which means it occasionally produces false positives, flagging someone as infected when they’re not. Performance also varies by geographic location: in a multi-site international study, accuracy ranged from 84% concordance with gold-standard testing in some regions to 100% in others.
In practice, this means a positive HSV-1 blood test is very likely correct, but a positive result in someone with no history of symptoms and no known exposure could occasionally be wrong. Routine screening for HSV-1 is not standard practice in most clinical settings partly for this reason, and partly because the infection is so common that a positive result rarely changes medical recommendations.
HSV-1 vs. HSV-2
HSV-1 and HSV-2 are closely related but behave differently. HSV-1 traditionally causes oral herpes (cold sores) and is primarily spread through non-sexual contact in childhood. HSV-2 causes most cases of genital herpes and is almost exclusively sexually transmitted. HSV-2 is far less common: roughly 12% of Americans aged 14 to 49 carry it, compared to 48% for HSV-1.
The lines between the two have blurred somewhat. HSV-1 now accounts for a growing share of new genital herpes cases, particularly among young adults in countries where childhood oral infection rates have dropped. When someone reaches adulthood without prior HSV-1 exposure, their first encounter with the virus through oral sex can result in a genital HSV-1 infection. Genital HSV-1 tends to recur less frequently than genital HSV-2, but it’s still a lifelong infection.